Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Jean-Baptiste Fraison , Arsène Mekinian (1) , Eric Grignano , Jean-Emmanuel Kahn , Jean-Benoît Arlet , Olivier Decaux (2) , Denis Guillaume , Anne-Laure Buchdahl , Mohamed Omouri , Gwenola Maigne , Achille Aouba , Nathalie Leon , Sabine Berthier (3) , Eric Liozon (4) , Sophie Park , Claude Gardin (5) , Olivier Lortholary (6, 7) , Julien Rossignol , Pierre Fenaux , Olivier Fain (1) , Thorsten Braun (5)

1 CHU Saint-Antoine [AP-HP]
2 IGDR - Institut de Génétique et Développement de Rennes
3 CAPS - Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093]
4 Service de Médecine interne A et polyclinique médicale [CHU Limoges]
5 Service d'hématologie clinique [Avicenne]
6 Centre d'infectiologie Necker-Pasteur [CHU Necker]
7 IMAGINE - U1163 - Imagine - Institut des maladies génétiques

57th Annual Meeting of the American-Society-of-Hematology Location: Orlando, FL Date: DEC 05-08, 2015

Domains: Life Sciences [q-bio]

Jean-Baptiste Fraison, Arsène Mekinian, Eric Grignano, Jean-Emmanuel Kahn, Jean-Benoît Arlet, et al.. Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Blood, 2015, 126 (23), pp.1695. ⟨hal-01300814⟩